Saturday 17 October 2026 Export KIDS’s income statement to Excel — free account

OrthoPediatrics Corp.

OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.4%, EPS was flat, free cash flow grew 77.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

21.95 0.62 −2.75%

Follow KIDS

Alert me

Market cap: $589.3M
P/E: 0.0×
Fwd P/E: −15.7×
Dividend yield: —
F-score: 4/9
Altman Z: 1.49
Beneish M: −2.67
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 47.75

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	5	—	—	—	—	6	6	—

Insider Ownership 24.32%

Capital & Financial Ratios $m

Market Cap 589.30

Revenue 252.73

Net Income (39.73)

Free Cash Flow (1.83)

Net Debt 49.67

Current Ratio 4.78

Debt/Equity 0.28

P/E ratio 0.00

Fwd P/E (15.70)

P/S ratio 2.09

P/B ratio 1.54

Past 5Y EPS Growth —

This Y EPS Growth 28.11%

Next Y EPS Growth 32.20%

Next Y revenue growth 12.97%

Next 5Y EPS Growth 37.73%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.89%

10-year low 10-year high

P/B against its own 10 years 19.41%

10-year low 10-year high

EV/Sales against its own 10 years 16.51%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	82	71	63	48
Receivables	35	42	54	61
Inventory	106	117	134	138
Other	—	—	—	—
	226	237	256	253

	2023	2024	2025	Q'26
Payables	13	9	19	22
ST’ Debt	0	0	0	0
Other	18	11	14	15
	42	34	46	53

Compound Annual Growth %

	10y	5y	3y
Sales	22.52%	27.16%	24.56%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	8.10%	(2.91%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	59	71	—	—	—
’25	52	61	61	62	236
’24	45	53	55	53	205
’23	32	40	40	38	149
’22	23	33	35	31	122
’21	21	27	25	25	98
’20	16	14	22	19	71

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	1	—	—	—
’25	(4)	(10)	(1)	10	(5)
’24	(7)	(6)	(10)	(4)	(27)
’23	(6)	(4)	(9)	(8)	(27)
’22	(4)	(8)	(6)	(3)	(22)
’21	(2)	(9)	(1)	(1)	(13)
’20	(7)	(8)	(4)	0	(19)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(8)	(14)	(3)	10	(16)
’24	(13)	(13)	(12)	(4)	(41)
’23	(11)	(10)	(11)	(13)	(46)
’22	(8)	(13)	(7)	(3)	(32)
’21	(8)	(11)	(8)	(3)	(29)
’20	(11)	(10)	(5)	(4)	(30)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.45)	(0.30)	—	—	—
’25	(0.46)	(0.30)	(0.50)	(0.43)	(1.69)
’24	(0.34)	(0.26)	(0.34)	(0.69)	(1.64)
’23	(0.30)	(0.13)	(0.20)	(0.29)	(0.92)
’22	(0.47)	(0.02)	0.87	(0.35)	0.06
’21	(0.54)	(0.19)	(0.11)	0.00	(0.84)
’20	(0.30)	(0.54)	(0.24)	(0.73)	(1.82)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	17.03	14.00	28.19	32.21	38.96	35.67	23.10	21.02	15.28	Analyst estimates 2026–2028 Powerpack
	High	—	23.00	39.81	47.82	55.98	73.91	61.27	53.50	35.99	27.60
People
People	Employees	62	69	80	94	116	133	203	247	562	602
	Revenue/emp, $m	0.60	0.66	0.72	0.77	0.61	0.74	0.60	0.60	0.36	0.39
Income, $m
Income, $m	Revenue	37	46	58	73	71	98	122	149	205	236
	Gross margin, %	70.69	75.52	74.15	75.28	77.42	74.86	74.14	74.80	72.58	73.05
	EBT	(7)	(9)	(12)	(13)	(34)	(17)	(4)	(21)	(42)	(39)
	EBT margin, %	(17.62)	(19.58)	(20.89)	(17.48)	(47.37)	(17.73)	(3.02)	(14.33)	(20.48)	(16.58)
	Net income	(7)	(9)	(12)	(14)	(33)	(16)	1	(21)	(38)	(40)
	Depreciation	2	2	3	5	8	11	17	18	21	28
Per share, $
Per share, $	Revenue	21.39	11.36	4.58	4.96	3.94	5.09	5.91	6.56	8.87	10.07
	Earnings	(3.77)	(6.12)	(0.96)	(0.94)	(1.82)	(0.84)	0.06	(0.92)	(1.64)	(1.69)
	Cash flow	(0.64)	(1.80)	(1.24)	(1.22)	(1.03)	(0.68)	(1.05)	(1.19)	(1.17)	(0.21)
	Capex	(2.73)	(1.63)	(0.43)	(0.83)	(0.63)	(0.83)	(0.48)	(0.84)	(0.62)	(0.47)
	Free cash flow	(3.37)	(3.43)	(1.67)	(2.04)	(1.65)	(1.51)	(1.54)	(2.03)	(1.79)	(0.68)
	Book value	3.44	11.82	6.50	9.73	13.00	11.70	18.29	16.63	15.36	14.77
	Shares, m	2	4	13	15	18	19	21	23	23	23
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	1,024.25	0.00	0.00	0.00
	P/S	0.77	1.91	7.62	9.47	10.48	11.76	6.94	5.03	2.61	1.76
	P/B	0.00	1.84	5.36	4.83	3.17	5.12	2.24	1.99	1.51	1.20
	EV/Sales	1.35	1.54	6.93	8.84	9.30	11.21	5.96	4.55	2.62	1.91
	EV/FCF	(5.95)	(5.10)	(18.95)	(21.48)	(22.15)	(37.82)	(19.80)	(14.69)	(12.36)	(24.95)
Cash, $m
Cash, $m	Operating cash flow	(1)	(7)	(16)	(18)	(19)	(13)	(22)	(27)	(27)	(5)
	Capex	(5)	(7)	(5)	(12)	(11)	(16)	(10)	(19)	(14)	(11)
	Free cash flow	(6)	(14)	(21)	(30)	(30)	(29)	(32)	(46)	(41)	(16)
Balance, $m
Balance, $m	Working capital	14	60	88	114	123	104	196	185	203	210
	Total debt	18	25	21	26	1	1	1	10	72	97
	Net debt	16	(17)	(39)	(46)	(84)	(54)	(119)	(72)	2	34
	Shareholders’ equity	6	47	82	142	235	225	379	377	355	347
Returns, %
Returns, %	ROA	(81.16)	(41.65)	(12.37)	(9.33)	(13.11)	(5.21)	0.34	(4.84)	(8.29)	(8.08)
	ROIC	(17.47)	(13.32)	(14.11)	(5.88)	(11.10)	(6.57)	(6.11)	(5.49)	(6.14)	(6.44)
	ROE	139.76	264.17	(18.61)	(12.25)	(17.47)	(7.07)	0.41	(5.55)	(10.34)	(11.31)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CTKB Cytek Biosciences, Inc.	$703.2M	— (loss-making)	— (loss-making)	+5.57% (above 0%: growing)	n/m	+42.50% (above 0%: growing)	58.87%	(23.68%)	Compare
PACB Pacific Biosciences of California, Inc.	$609.2M	— (loss-making)	— (loss-making)	−1.91% (below 0%: shrinking)	n/m	−30.97% (below 0%: shrinking)	32.40%	(114.36%)	Compare
KIDS OrthoPediatrics Corp.	$589.3M	— (loss-making)	— (loss-making)	+15.43% (above 0%: growing)	n/m	+77.59% (above 0%: growing)	74.27%	(5.77%)
TCMD Tactile Systems Technology, Inc.	$527.6M	20.5×	22.7×	+8.61% (above 0%: growing)	+142.86% (above 0%: growing)	−86.53% (below 0%: shrinking)	76.25%	7.97%	Compare
SSII SS Innovations International, Inc.	$517.2M	— (loss-making)	— (loss-making)	+39.39% (above 0%: growing)	n/m	−16.62% (below 0%: shrinking)	50.94%	(16.29%)	Compare
DCTH Delcath Systems, Inc.	$513.9M	1,408×	— (loss-making)	+20.60% (above 0%: growing)	−12.50% (below 0%: shrinking)	−24.45% (below 0%: shrinking)	89.75%	8.22%	Compare
MASS 908 Devices Inc.	$491.5M	— (loss-making)	— (loss-making)	+23.31% (above 0%: growing)	n/m	+150.95% (above 0%: growing)	51.90%	(79.69%)	Compare
SGHT Sight Sciences, Inc.	$484.8M	— (loss-making)	— (loss-making)	+19.55% (above 0%: growing)	n/m	+26.71% (above 0%: growing)	91.39%	(16.62%)	Compare
BWAY Brainsway Ltd. Sponsored ADR	$475.8M	24.8×	— (loss-making)	+35.43% (above 0%: growing)	+40.00% (above 0%: growing)	−51.68% (below 0%: shrinking)	74.62%	13.98%	Compare
Median of peers	$515.6M	24.8×	—	+20.07%	+40.00%	−20.53%	66.75%	(16.45%)

All 149 Medical Devices stocks →

OrthoPediatrics Corp. (KIDS) key facts

Strength: OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024.
OrthoPediatrics Corp. (KIDS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KIDS traded at $21.95, a market capitalization of $589.3 million.
Return on equity was −11.3% and debt-to-equity 0.28.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.49 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.